Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term renal and systemic effects of empagliflozin in non-diabetic patients with glomerular hyperfiltration
2019-004152-10Phase 2Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of empagliflozin in glomerular hyperfiltration, obesity and chronic kidney disease (CKD), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Change in measured GFR by iohexol plasma clearance. Started Jun 2021; status: terminated.
02
Drugs
empagliflozin
03
Conditions
glomerular hyperfiltrationobesitychronic kidney disease (CKD)
Beyond the preview
Go deeper on 2019-004152-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004152-10.